This database contains 24 studies, archived under the term: "lewy body disease"
Click here to filter this large number of results.
Addenbrooke’s Cognitive Examination validation in Parkinson’s disease
Reyes, M. A.,
Perez-Lloret, S.,
Roldan Gerschcovich, E.,
Martin, M. E.,
Leiguarda, R.,
Merello, M.
Background: There is a clear need for brief, sensitive and specific cognitive screening instruments in Parkinson’s disease (PD).; Objectives: To study Addenbrooke’s Cognitive Examination (ACE) validity for cognitive assessment of PD patient’s using the Mattis Dementia Rating Scale (MDRS) as reference method. A specific scale for cognitive evaluation in PD, in this instance the Scales […]
Levodopa use and sleep in patients with dementia with Lewy bodies
Sleep disturbance and excessive daytime somnolence (EDS) are features of Parkinson’s disease (PD) and dementia with Lewy bodies (DLB) that may be influenced by dopamine replacement therapy. The effect of levodopa on sleep and EDS in DLB is unknown and unclear in PD. The aim of this study is to determine if levodopa treatment alters […]
Efficacy and safety of memantine in Lewy body dementia
Lewy body dementia (LBD) is a progressive brain disease manifest as dementia and parkinsonism, along with psychotic and autonomic disorders. Although studies in recent years have demonstrated the positive effects of cholinesterase inhibitors in LBD, the search for therapeutic agents with other mechanisms of action remains relevant. An open, controlled, 16-week study was performed with […]
Detection of disease-associated α-synuclein in the cerebrospinal fluid: a feasibility study
Unterberger, Ursula,
Lachmann, Ingolf,
Voigtländer, Till,
Pirker, Walter,
Berghoff, Anna S.,
Flach, Katharina,
Wagner, Uta,
Geneste, Aline,
Perret-Liaudet, Armand,
Kovacs, Gabor G.
With the aim to evaluate the significance and reliability of detecting disease-specific α-synuclein in the cerebrospinal fluid (CSF) we developed an ELISA and bead-assay. We used a commercial antibody (5G4) that does not bind to the physiological monomeric form of α-synuclein, but is highly specific for the disease-associated forms, including high molecular weight fraction of […]
Additional use of Aβ₄₂/Aβ₄₀ ratio with cerebrospinal fluid biomarkers P-tau and Aβ₄₂ increases the level of evidence of Alzheimer’s disease pathophysiological process in routine practice
Sauvée, Mathilde,
DidierLaurent, Guerric,
Latarche, Clotilde,
Escanyé, Marie-Christine,
Olivier, Jean-Luc,
Malaplate-Armand, Catherine
Background: Cerebrospinal fluid (CSF) biomarkers have recently been included in the criteria for the diagnosis of Alzheimer’s disease (AD). Since interpretation of CSF profile requires the combination of three parameters, biological data are not always conclusive and isolated elevation of phosphorylated tau (P-tau) or reduction of amyloid-β (Aβ)42 alone can be observed. In these cases, […]
Impact of molecular imaging on the diagnostic process in a memory clinic
Ossenkoppele, Rik,
Prins, Niels D.,
Pijnenburg, Yolande A.L.,
Lemstra, Afina W.,
van der Flier, Wiesje M.,
Adriaanse, Sofie F.,
Windhorst, Albert D.,
Handels, Ron L.H.,
Wolfs, Claire A.G.,
Aalten, Pauline,
Verhey, Frans R.J.,
Verbeek, Marcel M.,
van Buchem, Mark A.,
Hoekstra, Otto S.,
Lammertsma, Adriaan A.,
Scheltens, Philip,
van Berckel, Bart N.M.
Background: [(11)C]Pittsburgh compound B ([(11)C]PIB) and [(18)F]-2-fluoro-2-deoxy-D-glucose ([(18)F]FDG) PET measure fibrillar amyloid-β load and glucose metabolism, respectively. We evaluated the impact of these tracers on the diagnostic process in a memory clinic population.; Methods: One hundred fifty-four patients underwent paired dynamic [(11)C]PIB and static [(18)F]FDG PET scans shortly after completing a standard dementia screening. Two-year […]
18F-FDG PET and perfusion SPECT in the diagnosis of Alzheimer and Lewy body dementias
O'Brien, J. T.,
Firbank, M. J.,
Davison, C.,
Barnett, N.,
Bamford, C.,
Donaldson, C.,
Olsen, K.,
Herholz, K.,
Williams, D.,
Lloyd, J.
Unlabelled: Brain imaging with glucose ((18)F-FDG) PET or blood flow (hexamethylpropyleneamine oxime) SPECT is widely used for the differential diagnosis of dementia, though direct comparisons to clearly establish superiority of one method have not been undertaken.; Methods: Subjects with Alzheimer disease (AD; n = 38) and dementia with Lewy bodies (DLB; n = 30) and […]
Efficacy of memantine in PDD and DLB: an extension study including washout and open-label treatment
Johansson, C.,
Ballard, C.,
Hansson, O.,
Palmqvist, S.,
Minthon, L.,
Aarsland, D.,
Londos, E.
Objective: This 30-week extension trial was a continuation of the first double-blind randomized controlled trial (RCT) to study memantine in dementia with Lewy bodies (DLB) and Parkinson’s disease dementia (PDD). The objective was to evaluate the presence of recurrence of symptoms upon drug withdrawal. Furthermore, the aim was to explore washout dynamics in order to […]